Multicenter Randomized Pragmatic Clinical Trial Comparing Two- Versus Three-Antibiotic Therapy for Pulmonary Mycobacterium avium Complex Disease

Brief description of study

The purpose of the study is to learn about three drugs typically used to treat pulmonary MAC: azithromycin, ethambutol, and rifampin. These drugs have not been approved by the Food and Drug Administration (FDA) for your condition, and therefore considered investigational as used in this study. However, these medications are recommended by the American Thoracic Society and Infectious Disease Society of America. The drug regimen of azithromycin and ethambutol will be called “the 2-study drug regimen” throughout this study. The drug regimen of azithromycin, ethambutol, and rifampin will be called “the 3-study drug regimen throughout this study. The study will compare two approaches for treating pulmonary MAC disease. Sometimes a 3-drug regimen is prescribed and sometimes a 2-drug regimen is prescribed. The two regimens will be examined to see if the 2-drug regimen is as effective and/or more tolerable than the 3-drug regimen.


Clinical Study Identifier: s19-00328
ClinicalTrials.gov Identifier: NCT03672630
Principal Investigator: Doreen J Addrizzo-Harris.
Other Investigators: Ashwin Basavaraj, Rudra Ramanathan.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.